Commitmentsmainlyrelate to Research and Development Agreements held with RoyalMelbourneInstitute

ofTechnology,forboththe Breeding and Pre-Clinical Research andtheLibrary of CannabinoidsProject,in addition

tothe Biotechnical Faculty of the University of Ljubljana.

During the nancial year a Letter of Intent was entered into with the Malta Enterprise for the allocation of industrial space to setup a

business in Malta for the growing and production of medical cannabis. Contingent on the allocation of a site, the Group are to invest

circa €4,300,000 in improvements to site, plant, machinery and equipment, to be implemented within three years from the date of

allocation of the site. As at the date of this report the formal allocation of the site is yet to be conrmed.

There were no further commitments nor contingent liabilities other than those disclosed as at 30 June 2018.

24. RELATED PARTY TRANSACTIONS

a) Key Management Personnel Remuneration

Disclosures relating to key management personnel are in the Directors Report.

b) Transactions with Director related entities

Directors and ofcers, or their personally-related entities, hold positions in other entities that result in them having controls or

signicant inuence over the nancial or operating policies of those entities.Details of the transactions including amounts accrued

but unpaid at the end of the year are as follows:

Notes to the Financial Statements

for capital raising fees and

administrative costs

mgcpharma.com.au